Prenatal Carrier Screening for Spinal Muscular Atrophy Among Thai Pregnant Women
1 other identifier
observational
200
1 country
1
Brief Summary
Spinal muscular atrophy (SMA) prenatal carrier screening is recommended by American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG). However, in Thailand, there are no standard protocol for SMA prenatal carrier screening.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2021
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 10, 2021
CompletedFirst Submitted
Initial submission to the registry
March 26, 2021
CompletedFirst Posted
Study publicly available on registry
April 26, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2022
CompletedApril 26, 2021
April 1, 2021
12 months
March 26, 2021
April 21, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Rate of acceptance of prenatal carrier screening for spinal muscular atrophy
Rate of acceptance of prenatal carrier screening for spinal muscular atrophy among pregnant women seeking prenatal care
12 months
Secondary Outcomes (4)
Factors associated rate of acceptance of prenatal carrier screening for spinal muscular atrophy
12 months
Copies number of SMN1 and SMN2 genes in pregnant women
12 months
Carrier frequency among individuals who accepted carrier screening
12 months
Pregnant women's attitudes toward spinal muscular atrophy and carrier screening
12 months
Eligibility Criteria
All pregnant women who came to antenatal care clinic at Ramathibodi Hospital, Mahidol University
You may qualify if:
- Maternal age \> 18 years
- Singleton pregnancy
- Gestational age ≤ 14 weeks
You may not qualify if:
- Refuse to participate the research trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Ratchathewi, Bangkok, 10400, Thailand
Biospecimen
blood, plasma and DNA
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Chayada Tangshewinsirikul
Ramathibodi Hospital, Mahidol University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 2 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Study Record Dates
First Submitted
March 26, 2021
First Posted
April 26, 2021
Study Start
March 10, 2021
Primary Completion
March 1, 2022
Study Completion
March 1, 2022
Last Updated
April 26, 2021
Record last verified: 2021-04